Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim

News   Dec 10, 2013

 
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
 
 
 

RELATED ARTICLES

Reversing an Unstoppable Cancer Cascade with Proteomics

News

Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.

READ MORE

A New, Streamlined Approach to Diagnosing and Treating Bowel Cancer

News

Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.

READ MORE

Fermentation Byproduct Suppresses Seizures in Nerve Agent Poisoning

News

A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE